Finch Therapeutics Group

Finch Therapeutics Group is a biopharma company developing therapeutics through the human microbiome in a human-first discovery platform.The company currently has an ongoing Phase 2 FDA clinical trial for recurrent C. difficile infection.

Patents solely owned by Finch:

US Patent Number

Covers the use of

Owned until

10,022,406

Donor-derived compositions

2031

9,901,603

Lyophilized formulations of microbial therapies

2036

9,962,413

Screened, healthy donors in the manufacture of microbial therapies

2031

9,962,414

Pharmaceutical compositions containing a plurality of Clostridium species

2021

Timeline

September 2020

Finch Therapeutics Group raises a $90,000,000 series D round from Avenir Growth Capital, Baupost Group, Humboldt Fund, MSD Capital, Msd Partners, L.P., OCV Partners, OMX Ventures, Octave Group, SIG, Shumway Capital, Symbiosis Group, Trans-Pacific Technology Fund and Willett Advisors LLC.

August 2019

Finch Therapeutics Group raises a $53,000,000 series C round from Avenir Growth Capital, Morgan Noble, OCV Partners, Shumway Capital, Susquehanna International Group, Symbiosis LLC, Trans-Pacific Technology Fund and Willett Advisors LLC.

March 2018

Finch Therapeutics Group raises a $36,000,000 series B round from Avenir Growth Capital, Morgan Noble, Shumway Capital and Willett Advisors LLC.

January 21, 2017

Finch Therapeutics Group raises a $3,700,000 venture round.

December 1, 2016

Finch Therapeutics Group raises a $5,600,000 series A round.